Evolus (NASDAQ:EOLS – Get Free Report) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare Evolus to similar companies based on the strength of its institutional ownership, profitability, earnings, risk, dividends, valuation and analyst recommendations.
Risk and Volatility
Evolus has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500. Comparatively, Evolus’ peers have a beta of -0.05, suggesting that their average share price is 105% less volatile than the S&P 500.
Earnings & Valuation
This table compares Evolus and its peers gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Evolus | $297.18 million | -$51.64 million | -15.04 |
| Evolus Competitors | $16.51 billion | $3.17 billion | 555.15 |
Evolus’ peers have higher revenue and earnings than Evolus. Evolus is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Profitability
This table compares Evolus and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Evolus | -9.56% | N/A | -11.10% |
| Evolus Competitors | -2,391.71% | -206.09% | -14.88% |
Analyst Ratings
This is a summary of current ratings and price targets for Evolus and its peers, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Evolus | 1 | 1 | 4 | 0 | 2.50 |
| Evolus Competitors | 7850 | 13806 | 25845 | 1039 | 2.41 |
Evolus currently has a consensus price target of $15.00, indicating a potential upside of 112.16%. As a group, “Pharmaceuticals” companies have a potential upside of 27.62%. Given Evolus’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Evolus is more favorable than its peers.
Institutional and Insider Ownership
90.7% of Evolus shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 5.0% of Evolus shares are owned by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Evolus beats its peers on 8 of the 13 factors compared.
Evolus Company Profile
Evolus, Inc. is a medical aesthetics company focused on developing and commercializing treatments for cosmetic procedures. The company’s portfolio includes injectable products used by healthcare professionals to address facial lines and wrinkles and to enhance facial appearance. Its flagship product, Jeuveau (prabotulinumtoxinA-xvfs), is a prescription botulinum toxin treatment for moderate to severe frown lines between the eyebrows in adults. Evolus also markets Evolysse, a line of hyaluronic acid dermal fillers designed for facial aesthetic treatments.
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.
